ERO1A (endoplasmic reticulum oxidoreductase 1 alpha) is a critical oxidoreductase enzyme that catalyzes disulfide bond formation in the endoplasmic reticulum through reoxidation of protein disulfide isomerase (PDI), generating reactive oxygen species as a byproduct 1. The enzyme plays essential roles in protein folding, particularly immunoglobulins, and maintains ER redox homeostasis 2. ERO1A functions through interaction with various ER proteins, including ERp44, which it can dissociate from ryanodine receptor complexes in cardiac tissue, contributing to calcium handling abnormalities and arrhythmias 1. In pathological conditions, ERO1A becomes significantly upregulated and promotes tumor progression across multiple cancer types, including breast, colorectal, bladder, and pancreatic cancers 3456. The protein drives oncogenic processes through multiple mechanisms: promoting angiogenesis via VEGF folding, creating immunosuppressive tumor microenvironments, activating JAK-STAT signaling pathways, and facilitating epithelial-mesenchymal transition 653. Therapeutically, ERO1A represents a promising target, as its inhibition induces immunogenic cell death, enhances anti-tumor immunity, and improves responses to immunotherapy without affecting normal cells 367.